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Abstract
In Japan, attention has increasingly focused on ensuring the quality of care, particularly in the area of cancer care.
The 2006 Basic Cancer Control Act reinforced efforts to ensure the quality of cancer care in a number of sectors,
including the role of government in ensuring quality. We initiated a government-funded research project to develop
quality indicators to measure the quality of care for five major cancers (breast, lung, stomach, colorectal, and liver
cancer) in Japan, and palliative care for cancers in general. While we successfully developed a total of 206 quality
indicators, a number of issues have been raised regarding the concepts and methodologies used to measure quality.
Examples include the choice between measuring the process of care versus the outcome of care; the degree to
which the process-outcome link should be confirmed in real-world measurement; handling of exceptional cases;
interpretation of measurement results between quality of care versus quality of documentation; creation of summary
scores; and the optimal number of quality indicators for measurement considering the trade-off between the mea-
surement validity versus resource limitations. These and other issues must be carefully considered when attempting
to measure quality of care, and although many appear to have no correct answer, continuation of the project
requires that a decision nevertheless be made. Future activities in this project, which is still ongoing, should focus on
the further exploration of these problems.
Introduction
In Japan, interest in ensuring the quality of patient
health care has recently increased. Although Japanese
citizens have enjoyed universal health insurance cover-
age for more than 40 years, concern has been expressed
at the lack of an efficient system for monitoring the
quality of care [1,2]. To date, quality monitoring has
been sporadic at best [3,4], and organized efforts to
improve quality have yet to be established. In the area
of cancer care, this concern led to the enactment of the
Cancer Control Act in 2006, which mandated that the
government adopt a leadership role and take responsi-
bility in ensuring the quality of cancer care nationwide
[5]. However, ensuring quality care first requires an effi-
cient means of measuring it.
To this end, in 2006 the Japanese government funded a
research project aimed at developing a system for mea-
suring the quality of cancer care, focusing primarily on
the five major types of cancer in Japan, namely breast,
lung, stomach, colorectal, and liver cancer, as well as
palliative care. Given that the project was aimed at mea-
suring quality in terms of how current best practice was
applied, rather than the general suitability of services
(such as waiting times or the comfort of hospital beds),
we sought extensive involvement from nationally recog-
nized clinical experts in respective clinical areas. Metho-
dology was under the direction of an epidemiologist and
a health services researcher, while the contents of quality
measurement were primarily defined by clinicians.
An overview of the study was published in Japanese [6].
Briefly, we developed a total of 206 process-of-care quality
indicators for cancer care using methodology developed
by the researchers at University of California, Los Angeles
and RAND Corporation [7-12]. This involved creating a
set of candidate quality indicators, compiling evidence to
support these indicators, and having a panel of multidisci-
plinary experts examine them for validity in two rounds of
rating (scale of 1-9), once before and once after a face-to-
face discussion. After discarding those indicators judged as
having low validity, 206 indicators remained, all of which
described the standards of care which define the target
patients and the care processes that need to be provided
to them. Example indicators are presented in Table 1.
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with quality measurement, such assessment must be
approached with care, while conscientiously addressing
a number of major issues. Although the study is still
underway, we describe here several issues of note and
our methods of addressing them in the hope that they
may be of value to researchers and policy makers devel-
oping similar quality measurement systems. Before con-
tinuing, however, we caution that there are no right
solutions or answers to these issues and questions and
instead remind readers that the decisions made here
were those which we believe best served the present
purpose.
Choosing to examine process vs. outcome
Quality of care is typically measured with regard to struc-
ture, process, or outcome [13,14]. Structural quality
refers to organizational and facility quality, such as the
number of specialists on staff, staff-patient ratio, and the
availability of high-technology equipment. Process quality
refers to the appropriateness of care provided during
patient encounters, such as the appropriateness of medi-
cations and the selection of therapies and follow-up. Out-
come measurement estimates the quality of care that
patients receive by examining what happens to patients
as a result of care, such as mortality after surgery and
readmission after discharge.
Establishing a quality monitoring system first requires
a decision on which level(s) should be addressed, taking
into consideration the relative strengths and weaknesses
of each. Given that the government has already enacted
structural requirements for hospitals seeking designation
as “designated cancer care hospitals,” [15] the choice for
the present quality measurement lies between process
and outcome. Outcome in cancer care is typically
measured by five-year survival [16,17], and given that
improvement of outcome is the general objective of
medicine, its importance is clear. Member hospitals of
the Japanese Association of Clinical Cancer Centers
(Zen-gan-kyo) acknowledged this in 2007 through their
initiation of public reporting of five-year survival rates
by facility [18].
However, outcome reflects not only the medical care
provided but other factors as well, such as patient base-
line health and compliance with medical advice. Any
comparison of quality across populations and facilities
or over time needs to statistically adjust for these fac-
tors, particularly patient-case mix [19]. Moreover, the
calculation of five-year survival is necessarily a five-year
p r o c e s s ,at i m el a gw h i c hw e a k e n st h em e a s u r e m e n t ’s
value in improving care [13].
In contrast, evaluation of process, involving the specific
focus on what is done to patients, is the most direct of
the three measurement schemes. Process quality indica-
tors describe what should be done to what type of patient
under which clinical conditions, and the results accord-
ingly highlight direct targets for improvement. Unlike
outcome, process does not require a lengthy five-year
period to obtain results once the measurement system is
established. Indeed, when integrated with electronic
order entry and medical records, process values can even
be used prospectively, as clinical reminders [20].
One challenge to using process measures is criteria
definition. Although quality indicators should be based
on clinical evidence, direct clinical evidence among
important populations (e.g. older persons) is occasionally
limited [10], and criteria must therefore be extrapolated
from studies in other populations (e.g. younger persons)
based on expert consensus. In this situation, we consid-
ered that the optimal methodology to examine the con-
sensus was that developed by the RAND Corporation, as
described above [7-12]. While this methodology is not
perfect [21], we expect that it will provide the least biased
set of quality indicators when appropriately performed,
Table 1 Example of quality indicators developed in our project
Denominator (target patients) Numerator (care processes indicated)
Patients with stage 3 colorectal cancer who have undergone
surgical resection
Patients who have received standard chemotherapy within 8 weeks of surgery or
who have reasons for not receiving chemotherapy
Patients with colorectal cancer who have undergone surgical
resection
Patients who have received total colonoscopy or who have reasons for not
receiving total colonoscopy
Patients with gastric cancer who have undergone endoscopic
resection and have one of the following:
￿ positive vertical margin
￿ lymphovascular invasion
￿ invasion to the SM2 layer (≥500 μm)
Patients who have received surgical treatment with lymph-node dissection
Patients diagnosed with breast cancer Patients who have had their Her-2/neu status examined
Patients receiving treatment for liver cancer Patients who have had the levels of a-fetoprotein and protein in vitamin K
absence-II checked before the start of therapy
Patient with lung cancer who have undergone surgical
resection or radiation therapy on their lungs
Patients whose lung function has been assessed via spirometry
Patient receiving narcotic analgesics Patients who have received education or medication to prevent constipation
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using this methodology is reproducible [22,23] and agree
with the opinions of practicing physicians [24] and have
predictive validity [25].
Proving the process-outcome link
To qualify as a valid process quality indicator, a particular
standard of care should help to improve patient outcome;
if it does not, the provision of such care cannot be con-
sidered high-quality. Donabedian called this the “contri-
butional validity” of the process measure [13]. The lack
of direct clinical evidence from randomized controlled
trials encountered in many clinical situations sometimes
renders contributional validity ambiguous, and clinicians
can present different interpretations of evidence from
those of the expert panel members who helped to
develop an indicator, particularly with indicators devel-
oped based on indirect evidence. Typical examples of
such lack of direct evidence occur with quality indicators
that target diagnostic standards: although computer
tomography (CT) of the liver before colon cancer surgery
is a standard of care, for example, on the basis that CT
scan results affect treatment decisions and can thus be a
quality indicator, no randomized controlled trial has
examined the utility of CT of the liver before surgery.
Indeed, few diagnostic procedures have been subject to
randomized controlled trials.
Several points must be carefully considered before
examining the relationship between the process quality
measured and outcomes. First, the unit of analysis must
be identified. When comparing outcomes of patients who
do or do not receive a certain therapy, for example, the
patient is the unit of analysis [25,26]. In comparing
adherence rates, in contrast, the facility is the unit
[27,28]. Although the relationship at the aggregate level
does not necessarily imply the relationship at the indivi-
dual level, owing to the ecological fallacy [29], analysis at
the facility level will have acceptable validity if it is
accepted that the adherence rate represents the quality of
care provided by the facility, and incorporates other
aspects of care than those specifically measured in the
quality indicators. The appropriate unit of analysis will
depend on the unit’s comparability and the level at which
the quality data are available.
Second, as quality indicators may target different types
of outcomes, the outcomes themselves must be carefully
chosen [14]. The most common patient outcome in cancer
care is five-year survival, but not all high-level care pro-
longs life, or aims to prolong life. To list three examples,
suitable explanation of the risks and benefits of treatment
options is surely an aspect of quality, specifically the provi-
sion of respect to patient autonomy, but it is unlikely to
improve survival; administration of anti-emetic medica-
tions before chemotherapy is aimed at alleviating adverse
symptoms during therapy, and not to make any contribu-
tion to survival; and patient education about drug regi-
mens may increase compliance or reduce medication
errors. Although these may improve patient health or pre-
vent adverse events, their benefits may be too small to
detect from observation, yet they are strongly supported as
quality indicators.
Another point in considering the process-outcome
link may be the timing of outcome observation. This is
seen in any epidemiological study which examines the
cause-effect relationship [29]: outcomes of acute condi-
tions may be observed relatively early, while preventive
care processes will require some time to show results.
Evaluation of 100-year survival will show no impact of
quality no matter how high it may be. Though absurd,
this example highlights the importance of timing, and
the difficulty often met in determining the right timing
for a particular outcome.
Finally, interpretation of process-outcome links
observed in the real world requires caution. As rando-
mization of patients to high or low quality care is ethi-
cally untenable, studies examining quality-outcome
relationships are necessarily observational; and since
persons receiving high- and low-quality care may differ,
the level of evidence from such studies is lower than
that from randomized controlled trials, where optimum
comparability can be expected. If the content of a qual-
ity indicator (i.e., standard of care) is supported by ran-
domized controlled trials, its validity as an indicator
may not be refuted by a lack of relationship to outcomes
observed in clinical application, unless the target popu-
lation is extremely different.
Handling exceptions
No rule is free of exceptions. Although quality criteria
define which patients should receive which care processes,
some patients will not receive a particular item of care for
any of a number of reasons: for example, patients with
acute myocardial infarction should, by standard, receive
aspirin on admission, but this is of course foregone if the
patient is allergic to aspirin. In this case, “high quality” can
be defined as care that appropriately distinguishes excep-
tions from regular cases and tailors treatment to the indi-
vidual patient. Unfairly penalizing such cases as “failures”
to provide standard care should be avoided.
Three methods of handling exceptions to quality indica-
tors can be considered. First, these cases can be excluded
from the denominator in calculating the adherence rate,
thereby providing a “pure” sample of standard patients. In
our study also, denominators for some indicators were
made narrower than the population to which the numera-
tor care is usually applied in regular practice. This is
because we wanted a sample to whom the care is clearly
applicable. However, this method not only fails to give
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decisions of tailored medicine, but also lowers the
observed quality score (i.e. adherence rate to the quality
indicator), because subtracting the same number from
both the numerator and denominator actually decreases
the fraction when the fraction is less than 1 (for example,
(8-1)/(10-1) = 7/9 = 0.78 is less than 8/10 = 0.8). Further,
relatively small target populations can render quality
scores statistically unstable, with large standard errors.
A second method of handling exceptions is to treat
them as if the care had in fact been provided, provided
that the reason for the exception is properly documented.
In this way, atypical patients can be kept in the sample
and the care they receive can be evaluated in the same
way as for regular patients. Quality scores using this
method tend to be more stable than those using the first
method above, but patient eligibility for the quality indica-
tor becomes heterogeneous, which may then dilute the
link between the quality and the outcome by introducing
noise into the biological process-outcome link. While
acknowledging this limitation, we basically adopted this
second method of handling exceptions in the present
study. This can be seen in the fact that many of our quality
indicators explicitly demand documentation of the reason
why the indicated care was not provided (Table 1).
The third way of handling exceptions is to reduce tar-
get adherence by the expected number of exception
patients [30]. If 5% of patients ostensibly applicable to a
quality indicator are estimated to become exceptions,
the quality target can be set at 95% instead of 100%.
Given that identifying individual exceptions requires
that the researcher abstracting the medical record has
knowledge of treatment choices, which is occasionally
difficult due to a lack of detailed documentation [31], a
simple reduction in target enables the judgment of indi-
vidual cases to be avoided, and also thus the risk of
errors in such judgment. Further, gaming with the sys-
tem can be discouraged by labeling patients who did not
receive the indicated care as exceptions, perhaps retro-
spectively. In comparison of quality scores across popu-
lations, however, national variations in the proportion of
exception cases may introduce large random errors into
the comparison.
The above clearly demonstrate st h ed i f f i c u l t yi nh a n d -
ling exceptions. Even when considering only individual
cases, we may well refrain from stating that the target
quality score is 100%, or instead state outright that the
target is slightly lower than 100%. Indeed, the UK pay-
for-performance initiative (Quality and Outcomes Frame-
work) gives full points even for quality scores less than
100% [32,33], although they also allowed providers to
limit the denominators reporting exceptions. At the least,
quality information should be interpreted together with
data regarding the nature and number of exceptions
reported by providers [30,32,33].
Quality of care vs. quality of documentation
Quality scores depend to some extent on the quality of
available data. While process-of-care quality should ideally
be evaluated via direct observation, or perhaps in standar-
dized patients [34], information is typically collected from
medical records [9,35-37]. In addition, documentation of
essential clinical information, such as cancer stage and
follow-up review of drug regimens, consists of quality indi-
cators based on the notion that such documentation
represents an aspect of quality of care [31,38]. Both a reli-
ance on documentation for the implementation of quality
indicators and a specific focus on documentation among
several quality indicators leads to the impression that qual-
ity measurement overly emphasizes documentation, and
thereby begs the question of whether quality evaluation
measures the quality of medical care or the quality of
documentation.
Physicians who believe that documentation is a largely
separate issue from medical care may be reluctant to
accept that pertinent documentation is part of quality
care. Indeed, during our informal discussion about qual-
ity indicators, some clinicians practicing in urban areas
gave the example of providers in rural areas where a
small number of health professionals handle most medi-
cal issues. They noted that rural physicians may feel
particularly strongly about this aspect, as they are
usually too busy to keep detailed records and may not
need to communicate with the few other health profes-
sionals in their area through documentation, opting
instead for face-to-face conversations. However, having
sufficient documentation ensures smooth sharing of
information among health care professionals, supple-
menting face-to-face conversation. Given that a miscom-
munication is a major cause of medical errors [39],
quality of documentation can be safely deemed as falling
under the umbrella of quality of care, which will thereby
increase the probability of safe practices and improved
outcomes.
Scope of quality measures and number of
indicators
Medical care has various aspects, including not only
medical intervention but also patient education and
coordination of providers, and the long continuum
spanning prevention, diagnosis, treatment, and follow-
up. Narrow evaluation captures only limited aspects and
cannot represent the quality of care [40]. In addition,
evaluation based on a small number of quality criteria
can easily be gamed by providers allocating resources
only to satisfy the defined quality indicators and achieve
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haps more important aspects of care [41].
In contrast, broad measurement of quality covering
various aspects of care is resource- and labor-expensive.
Insurance claims data can be a suitable alternative, pro-
vided the necessary information is available; the range of
information is limited to the original utilization, how-
ever, and the data tend to lack details regarding patient
condition, such as laboratory and imaging results [42].
An empirical study examining broad aspects of quality
based on medical records found that quality indicators
that can be measured from claims data tended to result
in better scores than those requiring information from
medical records [43]. This finding suggests that selecting
quality indicators based on the availability of informa-
tion in insurance claims may fail to detect and solve
problems in quality of care. Instead, theoretically, selec-
tion should be primarily based on the importance of the
care process. Significant attention must be paid to the
balance between the validity of the quality measurement
and the resources spent on measurement.
Quality indicators in rare but important situations
Several issues must be considered when selecting quality
indicators by the priority of measurement. One such
issue is the expected effectiveness of the care indicated
in the quality measure, i.e. the potential for the care to
improve the patient’s outcome. Another issue is the
expected room for improvement in the practice being
evaluated; care processes which are known to be always
performed, for example, do not need to be re-examined.
A particularly controversial perspective is the number of
patients in whom the quality indicator is applicable. One
example is the need to perform additional surgical resec-
tion after endoscopic resection of a cancer which turned
out to be more deeply extended than initially estimated,
with a high risk of lymph node metastasis. Given that such
cases are relatively rare, however, including these quality
indicators in the measurement set may be inefficient,
because information needs to be collected from the entire
target patient population to determine whether the quality
indicator is applicable to them. In addition, when the
number of applicable patients is small, the denominator of
the quality score as the percent adherence is also small,
making scores calculated using adherence unstable. This
latter problem can be solved by obtaining a larger denomi-
nator through application of the indicator to a larger
population or for a longer duration; for example, even if
one quality indicator applies to only three patients in a
hospital annually, it may be applicable to 30 patients in a
town with 5 hospitals over a 2-year period. The impor-
tance of a quality indicator should therefore be judged on
a global scale; if the care process described in the indicator
strongly affects even a few patients, a decision should be
made based on contextual factors, such as whether or not
the indicator can be applied on a broader level to achieve
a sufficient number of applicable patients.
Creating a summary score
Quality indicators are scored based on the percentage of
patients who receive the care described in them. Our
cancer project produced 206 quality scores. When
reviewing the results, the research team felt that inter-
preting such many scores was difficult. To summarize
them, we therefore produced an overall number of
adherence to the indicators by dividing the total number
of patients to whom the quality indicator care was pro-
vided (sum of all numerators) by the total number of
times the quality indicator was applicable to the sample
patients (sum of all denominators). Although this score
has the conceptually reasonable meaning of “overall per-
formance of standards by the provider,” we then specu-
lated whether all indicators should have equal weight in
calculating the summary score, given that quality indica-
tors appeared to have different degrees of importance.
In particular, for those who do not think documentation
is important, documentation indicators must have smal-
ler weights than other indicators.
Creating summary score weighting for quality indica-
tors presents a challenge [44]. While the overall perfor-
mance is one-way, this orientation ignores the natural
importance of the care processes. An indicator’sw e i g h t
can relate to the comparative importance of the care
process; for example, providing oxygen to a hypoxic
patient is more important–at that moment–than docu-
menting stage of cancer within one month of diagnosis.
Assessment of comparative importance can be aided
by reviewing the expected improvement in outcome if
the care is provided. However, when quality indicators
target different stages of management of a disease, the
comparison requires clinical judgment. For example,
when determining whether or not prescribing anti-
emetic medications before starting chemotherapy is
more (or less) important than examining the entire colon
before surgery, we must consi d e rt h ed i f f e r e n c ei nt h e
basic nature of the outcomes expected to be improved by
these care processes. Clinical judgment can be elicited
either directly in the context of quality measurement by
expert ratings of overall importance of quality indicators,
as done by Ashton et al [45]., or by focusing solely on
outcome by asking clinicians about the overall degree of
outcome improvement on a single scale, integrating the
expected different outcomes such as survival and quality
of life, as is done by the indicator selection at the
National Comprehensive Cancer Network [46], albeit
that this is not to assign weights but to rank quality indi-
cators by their priority. Future studies should assess the
validity and reliability of such methodologies.
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weights is to create a rule which integrates multiple qual-
ity indicators, such as the all-or-none rule [47]. Under
this rule, several quality indicators are grouped together,
and patients who receive all the indicated care according
to the quality indicator set are counted. For example, if a
patient is eligible for quality indicators A, B, and C, s/he
is counted as having received quality care only if s/he has
received all the care described in indicators A, B, and C.
If s/he receives care in quality indicator A and B, but not
C, s/he is not counted as having received the care. The
quality score for a facility or patient group is then defined
as the proportion of patients who received “perfect” care
in the quality indicator set. Use of this strategy is sup-
ported by the notion that care is interrelated, and that
only receiving all necessary care in the target area is
acceptable. However, the score then depends on the
grouping of the quality indicators, which must be theore-
tically justifiable, and most importantly, determined
before the start of measurement. Further, if multiple such
groups are created, weighting of scores may again
become an issue, presenting new problems. In addition,
handling of exceptions to quality measurement becomes
increasingly important, as mistakenly entering one qual-
ity indicator event that should have been excluded
reduces the whole count for a patient.
In our present study, we have not yet decided on the
best method of calculating the summary score. Several
approaches will likely need to be tested, and discussions
among members of the research team and related clini-
cians will be conducted to address the possible options.
Conclusion
A number of issues must be addressed when developing
process quality indicators for cancer care, several of
which are reviewed here. While our project specifically
targets cancer care, many of these issues may also apply
in other clinical areas. Future researchers should not
expect to find the “right answers” to these issues and
questions, but rather should make decisions based on
best judgment, and thereby ensure progress. While dif-
ferent systems can call for different decisions, compari-
son of quality across patient populations (e.g., several
facilities or over time) requires recognition of the fact
that these decisions must be consistent across the com-
pared groups.
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